The effect of beta-adrenoceptor blocking agents, with differing ancillary properties, on the arrhythmias resulting from acute coronary artery ligation in anaesthetized rats

British Journal of Pharmacology
C A Campbell, J R Parratt

Abstract

The effects of several beta-adrenoceptor blocking agents, [+), (-) and (+/-)-oxprenolol, p-oxprenolol, practolol, propranolol and timolol) were investigated on the ventricular arrhythmias occurring within the first 30 min of acutely ligating the main left coronary artery in anaesthetized rats. The degree of cardiac and vascular beta-adrenoceptor blockade was also assessed. All the compounds exhibited antiarrhythmic activity under these conditions. The degree of cardiac beta-adrenoceptor blockade required for this protection was less for the cardioselective agents, p-oxprenolol and practolol, than for the non-selective beta-adrenoceptor blocking agents. A comparison of the two isomers of oxprenolol demonstrated that the (-)-isomer markedly suppressed ischaemic arrhythmias (ventricular ectopic beats, incidence and duration of ventricular tachycardia and duration of ventricular fibrillation) more effectively than the (+)-isomer. Compounds possessing intrinsic sympathomimetic activity (ISA) caused less marked haemodynamic changes (in equivalent beta-blocking doses) than those that did not possess this ancillary property. The membrane stabilizing activity of oxprenolol and p-oxprenolol did not appear to contribute to the antiarrhyth...Continue Reading

References

Jun 1, 1979·Proceedings of the Society for Experimental Biology and Medicine·Z J BosnjakJ P Kampine
Apr 1, 1965·British Journal of Pharmacology and Chemotherapy·A MORALES AGUILERA, E M VAUGHANWILLIAMS

Citations

Oct 20, 2009·Basic Research in Cardiology·Dimitrios L OikonomidisTheofilos M Kolettis
Apr 16, 1985·European Journal of Pharmacology·D W HarronW Kobinger
Jan 1, 1985·Molecular Aspects of Medicine·J H BottingM J Walker
Nov 1, 1995·Clinical and Experimental Pharmacology & Physiology·L N Maslov, Y B Lishmanov
Apr 7, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Laura A HundahlThomas Jespersen
Sep 28, 1999·Clinical and Experimental Pharmacology & Physiology·Y B LishmanovD S Ugdyzhekova

Related Concepts

Adrenergic beta-Antagonists
Anesthesia Procedures
Metazoa
Cardiac Depressants
Cardiac Arrhythmia
Plasma Membrane
Sinus Node Artery
Hemodynamics
Novodrin
August Rats

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.